ANXA13

Summary

ANXA13 (annexin A13, HGNC:536) is a protein-coding gene on chromosome 8q24.13, encoding Annexin A13 (P27216). Binds to membranes enriched in phosphatidylserine or phosphatidylglycerol in a calcium-dependent manner.

This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. The specific function of this gene has not yet been determined; however, it is associated with the plasma membrane of undifferentiated, proliferating endothelial cells and differentiated villus enterocytes. Alternatively spliced transcript variants encoding different isoforms have been identified.

Source: NCBI Gene 312 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 82 total — 4 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_004306

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:536
Approved symbol	ANXA13
Name	annexin A13
Location	8q24.13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000104537
Ensembl biotype	protein_coding
OMIM	602573
Entrez	312

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 8 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000262219, ENST00000419625, ENST00000519045, ENST00000520519, ENST00000520591, ENST00000523822, ENST00000862979, ENST00000862980, ENST00000862981, ENST00000862982, ENST00000962456

RefSeq mRNA: 2 — MANE Select: NM_004306 NM_001003954, NM_004306

CCDS: CCDS34939, CCDS47917

Canonical transcript exons

ENST00000419625 — 11 exons

Exon	Start	End
ENSE00000703223	123688871	123688946
ENSE00000703231	123695688	123695721
ENSE00000703234	123698389	123698559
ENSE00000871715	123693197	123693298
ENSE00000871716	123693711	123693779
ENSE00000981342	123702642	123702736
ENSE00000981343	123695502	123695581
ENSE00001292122	123737320	123737393
ENSE00001308806	123684610	123684722
ENSE00002134040	123680794	123681359
ENSE00003576382	123712678	123712753

Expression profiles

Bgee: expression breadth ubiquitous, 149 present calls, max score 98.37.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.0216 / max 367.8843, expressed in 57 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
94740	0.9556	41
94739	0.0334	15
94741	0.0326	15

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gall bladder	UBERON:0002110	98.37	gold quality
jejunal mucosa	UBERON:0000399	97.14	gold quality
duodenum	UBERON:0002114	95.14	gold quality
right uterine tube	UBERON:0001302	94.96	gold quality
rectum	UBERON:0001052	90.36	gold quality
pancreatic ductal cell	CL:0002079	89.05	silver quality
small intestine Peyer’s patch	UBERON:0003454	87.87	gold quality
small intestine	UBERON:0002108	87.86	gold quality
mucosa of transverse colon	UBERON:0004991	85.02	gold quality
mucosa of sigmoid colon	UBERON:0004993	82.23	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	81.93	gold quality
ileal mucosa	UBERON:0000331	81.76	gold quality
seminal vesicle	UBERON:0000998	81.22	gold quality
epithelial cell of pancreas	CL:0000083	80.96	gold quality
transverse colon	UBERON:0001157	80.09	gold quality
colonic mucosa	UBERON:0000317	79.98	gold quality
intestine	UBERON:0000160	78.84	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.63	gold quality
spinal cord	UBERON:0002240	77.71	gold quality
jejunum	UBERON:0002115	76.99	gold quality
large intestine	UBERON:0000059	75.61	gold quality
colon	UBERON:0001155	75.41	gold quality
right lobe of liver	UBERON:0001114	72.12	gold quality
sigmoid colon	UBERON:0001159	70.79	gold quality
fallopian tube	UBERON:0003889	69.64	gold quality
caput epididymis	UBERON:0004358	68.44	gold quality
liver	UBERON:0002107	68.28	gold quality
muscle layer of sigmoid colon	UBERON:0035805	68.13	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.38	gold quality
lower esophagus	UBERON:0013473	67.27	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-CURD-98	yes	527.09
E-GEOD-125970	yes	16.18
E-ANND-3	yes	10.63
E-MTAB-8410	yes	4.57
E-MTAB-5061	no	3.77

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting ANXA13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-486-5P	99.51	70.39	707
HSA-MIR-122B-5P	99.46	70.81	1457
HSA-MIR-455-5P	98.74	67.31	795
HSA-MIR-6868-3P	98.63	69.64	2259
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-3188	98.58	65.60	878
HSA-MIR-93-3P	98.15	66.65	1309
HSA-MIR-938	97.41	68.28	656

Literature-anchored findings (GeneRIF, showing 7)

• Genetic Screening Revealed the Negative Regulation of miR-310~313 Cluster Members on Imd Pathway during Gram-Negative Bacterial Infection in Drosophila. (PMID:38790230)
• The unique, conserved aspects of annexin A13 primary structure, gene organization, and genetic maps identify it as the probable common ancestor of all vertebrate annexins. (PMID:11961095)
• Ectopic overexpression of Annexin A13 was likewise sufficient to sensitize malignant breast cancer cells to treatment with Rapamycin. (PMID:20701074)
• High ANXA13 expression is associated with Refractory Lupus Nephritis. (PMID:26110394)
• ANXA13 is associated with colorectal cancer cell invasion in vitro, and with lymph node metastasis and poor survival in colorectal cancer patients (PMID:28423508)
• a mechanism for how the association of the ANX A13a isoform with the membrane is regulated (PMID:30610115)
• Intracellular Transport of Ribosome-Inactivating Proteins Depends on Annexin 13. (PMID:33119820)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	anxa13l	ENSDARG00000013613
danio_rerio	anxa14	ENSDARG00000100104
mus_musculus	Anxa13	ENSMUSG00000055114
rattus_norvegicus	Anxa13	ENSRNOG00000007980
drosophila_melanogaster	AnxB9	FBGN0000083
drosophila_melanogaster	AnxB11	FBGN0030749

Paralogs (12): ANXA10 (ENSG00000109511), ANXA11 (ENSG00000122359), ANXA1 (ENSG00000135046), ANXA7 (ENSG00000138279), ANXA3 (ENSG00000138772), ANXA9 (ENSG00000143412), ANXA5 (ENSG00000164111), ANXA2 (ENSG00000182718), ANXA4 (ENSG00000196975), ANXA6 (ENSG00000197043), ANXA8L1 (ENSG00000264230), ANXA8 (ENSG00000265190)

Protein

Protein identifiers

Annexin A13 — P27216 (reviewed: P27216)

Alternative names: Annexin XIII, Annexin-13, Intestine-specific annexin

All UniProt accessions (2): E5RIN3, P27216

UniProt curated annotations — full annotation on UniProt →

Function. Binds to membranes enriched in phosphatidylserine or phosphatidylglycerol in a calcium-dependent manner. Half-maximal membrane binding requires about 60 uM calcium. Does not bind to membranes that lack phospholipids with an acidic headgroup. Binds to membranes enriched in phosphatidylserine or phosphatidylglycerol in a calcium-dependent manner, but requires higher calcium levels for membrane binding than isoform A. Half-maximal membrane binding requires about 320 uM calcium.

Subunit / interactions. Monomer and homodimer.

Subcellular location. Apical cell membrane. Cell membrane. Cytoplasmic vesicle.

Tissue specificity. Detected in epithelial cells in colon and jejunum (at protein level). Detected in epithelial cells in jejunum.

Domain organisation. A pair of annexin repeats may form one binding site for calcium and phospholipid.

Similarity. Belongs to the annexin family.

Isoforms (2)

UniProt ID	Names	Canonical?
P27216-1	A, Anx13A, A13a	yes
P27216-2	B, Anx13B, A13b

RefSeq proteins (2): NP_001003954, NP_004297* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001464	Annexin	Family
IPR009166	ANX13	Family
IPR018252	Annexin_repeat_CS	Conserved_site
IPR018502	Annexin_repeat	Repeat
IPR037104	Annexin_sf	Homologous_superfamily

Pfam: PF00191

UniProt features (36 total): helix 18, repeat 4, sequence variant 3, mutagenesis site 3, strand 2, initiator methionine 1, chain 1, sequence conflict 1, turn 1, lipid moiety-binding region 1, splice variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6B3I	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P27216-F1	95.00	0.92

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Mutagenesis-validated functional residues (3):

Position	Phenotype
2	loss of myristoylation. loss of location at the cell membrane.
32–34	loss of dimerization. no effect on calcium-dependent membrane binding and location at the cell membrane.
73	slightly increased dimerization. decreases calcium-dependent membrane binding and location at the cell membrane.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 123 (showing top): GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_VESICLE_MEDIATED_TRANSPORT, MODULE_453, HNF1_Q6, GOBP_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, PUJANA_CHEK2_PCC_NETWORK, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_CELL_PERIPHERY, GOBP_GOLGI_TO_PLASMA_MEMBRANE_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_TRANSPORT, RGTTAMWNATT_HNF1_01, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, GOBP_NEGATIVE_REGULATION_OF_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE

GO Biological Process (3): cell differentiation (GO:0030154), negative regulation of Golgi to plasma membrane protein transport (GO:0042997), positive regulation of Golgi to plasma membrane protein transport (GO:0042998)

GO Molecular Function (4): phosphatidylserine binding (GO:0001786), calcium ion binding (GO:0005509), calcium-dependent phospholipid binding (GO:0005544), phosphatidylglycerol binding (GO:1901611)

GO Cellular Component (13): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), plasma membrane (GO:0005886), vesicle membrane (GO:0012506), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), apical plasma membrane (GO:0016324), cytoplasmic vesicle (GO:0031410), membrane raft (GO:0045121), extracellular exosome (GO:0070062), exocytic vesicle (GO:0070382)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phospholipid binding	3
cellular anatomical structure	3
regulation of Golgi to plasma membrane protein transport	2
Golgi to plasma membrane protein transport	2
anion binding	2
plasma membrane region	2
cellular developmental process	1
negative regulation of protein transport	1
negative regulation of protein localization to plasma membrane	1
positive regulation of protein transport	1
positive regulation of protein localization to plasma membrane	1
modified amino acid binding	1
metal ion binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
organelle membrane	1
vesicle	1
basal plasma membrane	1
apical part of cell	1
cytoplasm	1
intracellular vesicle	1
membrane microdomain	1
extracellular vesicle	1
transport vesicle	1
secretory vesicle	1

Protein interactions and networks

STRING

636 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANXA13	CSMD3	Q7Z407	833
ANXA13	EXT1	Q16394	742
ANXA13	TRPS1	Q9UHF7	726
ANXA13	NKX3-2	P78367	411
ANXA13	SGCA	Q16586	410
ANXA13	DYSF	O75923	404
ANXA13	LMO2	P25791	386
ANXA13	ANXA5	P08758	386
ANXA13	COL9A2	Q14055	361
ANXA13	DLX2	Q07687	353
ANXA13	APOBEC2	Q9Y235	353
ANXA13	ACRBP	Q8NEB7	352
ANXA13	ZPBP2	Q6X784	352
ANXA13	SPACA3	Q8IXA5	352
ANXA13	CYB5R2	Q6BCY4	348

IntAct

16 interactions, top by confidence:

A	B	Type	Score
DEUP1	HIP1	psi-mi:“MI:0914”(association)	0.530
SCCPDH	RPN1	psi-mi:“MI:0914”(association)	0.530
ARMC8	VWA8	psi-mi:“MI:0914”(association)	0.350
EDAR	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
DEFB109B	CHST10	psi-mi:“MI:0914”(association)	0.350
SIRT3	SRC	psi-mi:“MI:0914”(association)	0.350
ARMS2	PRKCA	psi-mi:“MI:0914”(association)	0.350
APBB1IP	ANXA13	psi-mi:“MI:0914”(association)	0.350
MSI2	ANXA13	psi-mi:“MI:0914”(association)	0.350
ANXA2	ANXA13	psi-mi:“MI:0914”(association)	0.350
SRPRA	ANXA13	psi-mi:“MI:0914”(association)	0.350
ZNF200	ANXA13	psi-mi:“MI:0914”(association)	0.350
YIPF3	EI24	psi-mi:“MI:0914”(association)	0.350
BCL2L12	MCM3AP	psi-mi:“MI:0914”(association)	0.350
ANXA13	NMT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (33): ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS), ANXA13 (Affinity Capture-MS)

ESM2 similar proteins: A2SW69, A5A6L7, A6NMY6, O35639, O35640, O97529, P04272, P07355, P07356, P08132, P08758, P09525, P12429, P13214, P13928, P14668, P14669, P14824, P14950, P17153, P17785, P19620, P22464, P24551, P24801, P26256, P27006, P27216, P48036, P50994, P51074, P55260, P70075, P81287, P93157, P97429, Q07936, Q29471, Q2Q1M6, Q3SWX7

Diamond homologs: A2SW69, A5A6L7, A5A6M2, A6NMY6, C0HJG9, C1L7Y4, C4QH88, O35639, O35640, O76027, O97529, P04083, P04272, P07150, P07355, P07356, P08132, P08133, P08758, P09525, P10107, P12429, P13214, P13928, P14087, P14668, P14669, P14824, P14950, P17153, P17785, P19619, P19620, P20072, P20073, P22464, P22465, P24551, P24639, P24801

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ANXA13	“up-regulates quantity”	NEDD4	relocalization

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 24 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Hemostasis	5	11.3×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	67
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
144138	GRCh38/hg38 8q24.13-24.21(chr8:122454392-128513076)x3	Pathogenic
154743	GRCh38/hg38 8q22.3-24.3(chr8:103306336-145068712)x3	Pathogenic
2671975	GRCh37/hg19 8q24.13-24.21(chr8:124534271-129054138)x4	Pathogenic
3245610	NC_000008.10:g.(?124515613)(126379127_?)del	Pathogenic

SpliceAI

2212 predictions. Top by Δscore:

Variant	Effect	Δscore
8:123681360:C:CC	acceptor_gain	1.0000
8:123684604:TCTTA:T	donor_loss	1.0000
8:123684605:CTTAC:C	donor_loss	1.0000
8:123684606:TTA:T	donor_loss	1.0000
8:123684607:TA:T	donor_loss	1.0000
8:123684608:A:AG	donor_loss	1.0000
8:123684719:CTCA:C	acceptor_gain	1.0000
8:123684720:TCA:T	acceptor_gain	1.0000
8:123684721:CA:C	acceptor_gain	1.0000
8:123684721:CAC:C	acceptor_gain	1.0000
8:123684723:C:CC	acceptor_gain	1.0000
8:123684728:C:CT	acceptor_gain	1.0000
8:123684729:A:T	acceptor_gain	1.0000
8:123693717:CAGAT:C	donor_gain	1.0000
8:123695599:A:T	acceptor_gain	1.0000
8:123712680:ATT:A	donor_gain	1.0000
8:123735753:A:AC	donor_gain	1.0000
8:123735754:C:CC	donor_gain	1.0000
8:123735754:CAGG:C	donor_gain	1.0000
8:123737315:CTT:C	donor_loss	1.0000
8:123737317:TA:T	donor_loss	1.0000
8:123737318:A:AC	donor_gain	1.0000
8:123737318:A:AG	donor_loss	1.0000
8:123737319:C:CT	donor_gain	1.0000
8:123737319:CATGA:C	donor_gain	1.0000
8:123681356:CCAC:C	acceptor_gain	0.9900
8:123681357:CAC:C	acceptor_gain	0.9900
8:123681357:CACC:C	acceptor_gain	0.9900
8:123681358:ACC:A	acceptor_loss	0.9900
8:123681360:C:A	acceptor_loss	0.9900

AlphaMissense

2072 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:123681330:G:C	F287L	0.983
8:123681330:G:T	F287L	0.983
8:123681332:A:G	F287L	0.983
8:123693298:C:G	A181P	0.977
8:123693728:C:G	A175P	0.973
8:123702681:C:A	R49S	0.971
8:123702681:C:G	R49S	0.971
8:123693718:A:G	L178P	0.970
8:123698462:A:G	L95P	0.969
8:123693727:G:T	A175D	0.966
8:123695554:A:T	V140D	0.964
8:123681295:A:T	V299D	0.962
8:123693773:G:T	R160S	0.962
8:123693260:G:C	F193L	0.960
8:123693260:G:T	F193L	0.960
8:123693262:A:G	F193L	0.960
8:123693212:A:C	F209L	0.958
8:123693212:A:T	F209L	0.958
8:123693214:A:G	F209L	0.958
8:123695566:A:T	L136H	0.958
8:123702706:A:G	L41S	0.957
8:123698406:A:G	C114R	0.953
8:123702662:A:C	Y56D	0.953
8:123693739:G:T	A171D	0.951
8:123681270:G:C	F307L	0.950
8:123681270:G:T	F307L	0.950
8:123681272:A:G	F307L	0.950
8:123688918:A:T	I224N	0.950
8:123693225:A:G	L205S	0.950
8:123698454:C:G	A98P	0.949

dbSNP variants (sampled 300 via entrez): RS1000022725 (8:123739135 C>A,T), RS1000055906 (8:123719321 C>G,T), RS1000076265 (8:123703757 A>G), RS1000146174 (8:123703492 T>A,C), RS1000153981 (8:123692666 T>A), RS1000234375 (8:123737689 G>A), RS1000258636 (8:123735974 G>A,T), RS1000269342 (8:123696591 G>A), RS1000370391 (8:123725557 T>C), RS1000433082 (8:123733498 A>C), RS1000623714 (8:123737584 G>A), RS1000657141 (8:123708810 G>A), RS1000730742 (8:123686422 T>C), RS1000731880 (8:123703548 A>T), RS1000768167 (8:123694442 C>G)

Disease associations

OMIM: gene MIM:602573 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): distal trisomy 8q (MONDO:0019882)

Orphanet (1): Distal duplication 8q syndrome (Orphanet:96100)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000857_3	Event-related brain oscillations	9.000000e-06
GCST003225_15	Pelvic organ prolapse (moderate/severe)	9.000000e-06
GCST005076_17	Breast cancer (estrogen-receptor negative)	2.000000e-08
GCST005077_8	Breast cancer	2.000000e-11
GCST006979_369	Heel bone mineral density	1.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004358	event-related brain oscillation
EFO:0009270	heel bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196076 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression	2
Tetrachlorodibenzodioxin	decreases expression, affects expression, affects cotreatment	2
propionaldehyde	decreases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
titanium dioxide	decreases expression	1
beta-lapachone	decreases expression	1
sodium arsenite	affects methylation	1
butyraldehyde	decreases expression	1
butylbenzyl phthalate	decreases expression	1
pentanal	decreases expression	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
nutlin 3	increases expression	1
abrine	decreases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Irinotecan	decreases expression	1
Air Pollutants	decreases expression	1
Aldehydes	decreases expression	1
Catechin	affects cotreatment, decreases expression	1
Cisplatin	increases expression, affects cotreatment	1
Dimethyl Sulfoxide	increases expression	1
Endosulfan	affects cotreatment, decreases expression	1
Folic Acid	affects expression	1
Hydrogen Peroxide	affects expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases expression	1
Cyclosporine	decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6106837	Binding	Induction of ANXA13 degradation in human MDA-MB-231 cells at 0.5 to 6 uM incubated for 24 hrs by Western blot analysis relative to control	Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.